Hepatitis is the inflammation of the liver, an infection that leads to health problems like liver cancer and liver transplants. Hepatitis C is the most widespread form of Hepatitis which is caused by HCV: Hepatitis C virus and usually spreads after coming into contact with infected blood or after having sex with an infected person. Hepatitis C can also be caused after being passed from mother to baby during childbirth.

Signs and symptoms of Hepatitis C include fatigue, muscle aches, yellow tinge to the skin and eyes. Since Hepatitis C is contagious, it can be prevented by avoiding contact with blood and other bodily fluids from anyone who is infected with Hepatitis C. The biggest drawback of Hepatitis C treatment is that there are no vaccines for the cure of this dreadful virus.

There are two stages of Hepatitis C – the stage 1 occurs soon after the infection, but many individuals do not have any symptoms till the later stage because of which roughly 50% individuals infected develop a chronic infection. And, since it has been left untreated for long, most of such people suffer from liver diseases. But, with the recent developments in the medical field, the treatments have become even more effective and it has become easier to cure people suffering from Hepatitis C.

MediMantra works relentlessly to help patients get more effective medications suffering from Hepatitis C so that not only the duration of the treatment is reduced but the efficaciousness is improved while the overall cost is constantly decreased.


Commonly sold under the name of Daklinza, Dacalatasvir is the medicine which is prescribed to cure chronic hepatitis C virus (HCV) genotypes 1 and 3 infection and is mostly taken along with sofosbuvir or the HCV protease inhibitor asunaprevir and ribavirin. Decalatasvir is a new direct- acting antiviral drug that targets different steps of the Hepatitis C Virus lifecycle. How it works? Decalatasvir interferes with the protein with the help of which the virus reproduces, hence curbing its chance to spread any further in the body. It is strictly advised to take Dacalatasvir only with sofosbuvir, hence if a patient discontinues with sofosbuvir permanently, then he should definitely avoid dacalatasvir.

Elbasvir and Grazoprevir (Zepatier)

A safe and well tolerated pill to cure Hepatitis C, Elbasvir and Grazoprevir is a one- pill- once a day option for the treatment of genotype 1 or 4 infections. The presence of amino acid 28, 30, 31 or 93 substitutes requires the additional intake of ribavirin for the pill to work effectively and also an extended therapy from 12 to 16 weeks. It is oral fixed dose combination of NS5A replication complex inhibitor and a later generation HCV protease inhibitor. If we look at the activity against the HCV genotypes, these are better than the earlier generation protease inhibitors. Further, it is a result of the failures from the first- generation protease inhibitors.

Glecaprevir and Pibrentasvir (Mavyret)

Glecaprevir – pibrentasvir is the first pangenotypic NS3/ 4A protease inhibitor- NS5A inhibitor combination is a better option to cure the chronic hepatitis C as it gives majority of patients a ribavirin free option unlike the other medicines. The drug is not suitable for the patients with decompensated cirrhosis because of the presence of the protease inhibitor. Clinical reports have shown 98-100% positive response rate amongst patients with genotypes 1, 2, 5 and 6. This is the least expensive treatment of Hepatitis C with lesser side effects.

Ledipasvir and Sofosbuvir [Harvoni]

This one-pill fixed-dose of a combination of Ledipasvir and Sofosbuvir is the most effective options for treating genotypes 1, 4, 5 and 6 Hep-C infection – as approved by the FDA. Hepatitis C virus BS5B polymerase is responsible for mediating HCV RNA replication and Sofosbuvir is a simple analog inhibitor of the same which, when combined with Ledipasvir, gives a revolutionary treatment drug with minimal side effects.

Ombitasvir, Paritaprevir, Ritonavir [Technivie]

Technivie is generally used with ribavirin for improving the chances of getting cured and provides an option for patients who have compensated cirrhosis. The symptoms of cirrhosis in such patients are not visible but there is a considerable scarring on the inner lining of the liver. This regimen is one-a-day all-oral treatment option which minimizes the pill burden on patients which is brought in by the so-called directly active antiviral options.

Ritonavir, Paritaprevir, Ombitasvir, with Dasabuvir [Viekira Pak]

An all-oral regimen, this combination can be a bit chunky for the patients and is recommended to only those who have compensated cirrhosis or a mild scarring inside the liver. A serious alternative to injections, Ritonavir, Paritaprevir, Ombitasvir, with Dasabuvir is helpful for patients with genotype 1a and 1b infections [with compensated cirrhosis] – patients with cirrhosis can cause severe damage to their liver with this combination.

Simeprevir [Olysio] and Sofosbuvir [Sovaldi]

Both Olysio and Sovaldi can be used together. They have provided an excellent option/alternative to the patients suffering from the genotype 1 HCV. Combination of the two has created a less extensive interaction between the drugs – it is also well tolerated as compared to the first-gen protease inhibitors. The previous combinations are not recommended because of the time it took for the treatment to get finalized and also due to the high toxicity levels.

Sofosbuvir-Velpatasvir [Epclusa]

This is arguably the most interferon-free combination available for the treatment of HCV genotypes 1 to 6. For patients suffering from genotype 3, Epclusa provides a single-pill option which can be taken without combining with ribavirin. If the patient has severe cirrhosis, the regimen can be taken with ribavirin but not in cases involving compensated cirrhosis. Eplusa is said to remove the Hep-C virus

Vosevi [Sofosbuvir, Voxilaprevir and Velpatasvir]

Vosevi contains medications from three HCV antiviral classes. When a triple DAA [direct acting antiviral] works for patients who have suffered treatment failure, a dual therapy with sofosbuvir and velpatasvir works for all genotype 1 patients, and more effectively. This combination works best for the patients who have taken some treatments before and are suffering from compensated or severe cirrhosis. Vosevi is approved by the FDA for the treatment of adults with chronic HCV.